Sophiris Bio, Inc. (SPHS) financial statements (2022 and earlier)

Company profile

Business Address 1258 PROSPECT STREET
LA JOLLA, CA 92037
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:12,53925,84429,0018,40022,70048,149
Cash and cash equivalents10,99816,08712,8005,8814,12314,839
Short-term investments1,5419,75716,2012,50018,57233,310
Other undisclosed cash, cash equivalents, and short-term investments   195 
Receivables 13128816 
Prepaid expense4009998464672,8253,598
Other undisclosed current assets256  (19)(5)48
Total current assets:13,19526,85629,9758,85625,53651,795
Noncurrent Assets
Property, plant and equipment424173678
Other noncurrent assets 1919191919
Total noncurrent assets:42123365597
TOTAL ASSETS:13,19926,87729,9988,89225,59151,892
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,0542,3312,2211,4755,8344,714
Accounts payable1,8628324599092,6331,470
Accrued liabilities1,1921,4991,7625662,3072,181
Employee-related liabilities    8461,063
Interest and dividends payable    48 
Debt1,920372 1,7715986,877
Other undisclosed current liabilities    (894)(1,063)
Total current liabilities:4,9742,7032,2213,2465,53810,528
Noncurrent Liabilities
Long-term debt and lease obligation5,0916,435 3,5725,343 
Long-term debt, excluding current maturities5,0916,435 3,5725,343 
Liabilities, other than long-term debt1,39910,08913,45316822883
Deferred compensation liability, classified  5716822 
Derivative instruments and hedges, liabilities1,39910,08913,396  883
Other undisclosed noncurrent liabilities     202
Total noncurrent liabilities:6,49016,52413,4533,7405,3651,085
Total liabilities:11,46419,22715,6746,98610,90311,613
Stockholders' equity
Stockholders' equity attributable to parent, including:1,7357,65014,3241,90614,68840,279
Common stock131,247131,247131,245113,880113,095111,204
Additional paid in capital26,71425,85423,90017,68317,05313,824
Accumulated other comprehensive income1009799999998
Accumulated deficit(156,326)(149,548)(140,920)(129,756)(115,559) 
Other undisclosed stockholders' equity attributable to parent     (84,847)
Total stockholders' equity:1,7357,65014,3241,90614,68840,279
TOTAL LIABILITIES AND EQUITY:13,19926,87729,9988,89225,59151,892

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues3332383722515,000
Revenue, net    5,000
Net investment income333238372251 
Cost of revenue
(Cost of Goods and Services Sold)
   (600)(600)(600)
Gross profit:33323837(578)(549)4,400
Operating expenses(15,139)(11,918)(10,306)(13,488)(30,040)(14,790)
Operating loss:(14,806)(11,680)(10,269)(14,066)(30,589)(10,390)
Nonoperating income (expense)8,3613,290(858)(709)(672)(859)
Foreign currency transaction loss, before tax    (1)(229)
Other nonoperating income (expense)22(48)(12)(41)(46)(240)
Interest and debt expense(684)(207)159(690)(726)(1,308)
Loss from continuing operations before equity method investments, income taxes:(7,129)(8,597)(10,968)(15,465)(31,987)(12,557)
Other undisclosed income (loss) from continuing operations before income taxes351(31)(196)1,2681,2751,908
Loss from continuing operations before income taxes:(6,778)(8,628)(11,164)(14,197)(30,712)(10,649)
Income tax expense     (500)
Net loss available to common stockholders, diluted:(6,778)(8,628)(11,164)(14,197)(30,712)(11,149)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(6,778)(8,628)(11,164)(14,197)(30,712)(11,149)
Comprehensive loss:(6,778)(8,628)(11,164)(14,197)(30,712)(11,149)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3(2)  1144
Comprehensive loss, net of tax, attributable to parent:(6,775)(8,630)(11,164)(14,197)(30,711)(11,005)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: